作者mcasp (stanley)
看板Anti-Cancer
标题Re: [问题] 请问何种情形不适合服用爱瑞沙???
时间Tue Nov 29 03:06:21 2005
※ 引述《prehn (dicey and paltry)》之铭言:
: ※ 引述《winibaby (winibaby的冒险)》之铭言:
: : 不好意思 我想请问一下
: : 因为他听说可以治疗 肺癌
: : 希望有人可以解惑谢谢
: : 而且吃他的副作用有可能有间质性肺炎
: : 是什麽情形呢??
: 只能用在非肺小细胞癌罗...
: 最好有EGFR MUTATION, EXON 16,17,18 吧...
还要在後面壹点 exon 18, 19, 20, 21
卓参 详见 paper from CGMH VGH-TPE
Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor
Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients
with Non–Small Cell Lung Cancer
Clin. Cancer Res. 2005 11: 3750-3757.
High Frequency of Epidermal Growth Factor Receptor Mutations
with Complex Patterns
in Non–Small Cell Lung Cancers Related to
Gefitinib Responsiveness in Taiwan
Clin. Cancer Res. 2004 10: 8195-8203.
sorry 我打字 慢 to put it in English
exon 18, 19, 20, 21 are the tyrosin kinase domain untill exon 21
Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al.
(2004) EGF receptor gene mutations are common in lung cancers from “
never smokers” and are associated with sensitivity of tumors to
gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306–13311
: 效果一到二成.....
: 但我有看过效果不错的...吃二个多月. 肿瘤全消...
: 但他的EGFR MUTATION 好像有 PRESENT
: TARCEVA 也是新一代的罗...
irresa seems to be ALMOST withdrawal or LIMITED in its indication as FDA
announced (IRRESA withdraw its application in European market)
http://www.fda.gov/cder/drug/infopage/iressa/iressaQ&A2005.htm
Date created: June 17, 2005
(this is due to the fact that the end point of trial IDEAL or what ?(ISEL)
showed no advantage, comparing irresa and placebo)
TARCEVA now turn to "the only" FDA approved EGFR-TKI
Are TARCEVA related to anti-angiogenesis ?
: EGFR-TKI
: 知道就这些啦....
: m34789
--
※ 发信站: 批踢踢实业坊(ptt.cc)
◆ From: 192.192.90.202